Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Assets (2020 - 2025)

Historic Current Assets for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $155.5 million.

  • Caribou Biosciences' Current Assets fell 3450.34% to $155.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.5 million, marking a year-over-year decrease of 3450.34%. This contributed to the annual value of $219.4 million for FY2024, which is 3525.67% down from last year.
  • Latest data reveals that Caribou Biosciences reported Current Assets of $155.5 million as of Q3 2025, which was down 3450.34% from $192.5 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Current Assets high stood at $449.0 million for Q3 2021, and its period low was $143.0 million during Q2 2021.
  • Its 5-year average for Current Assets is $281.5 million, with a median of $269.7 million in 2023.
  • In the last 5 years, Caribou Biosciences' Current Assets skyrocketed by 150944.62% in 2021 and then plummeted by 3525.67% in 2024.
  • Quarter analysis of 5 years shows Caribou Biosciences' Current Assets stood at $391.2 million in 2021, then crashed by 33.47% to $260.2 million in 2022, then surged by 30.2% to $338.8 million in 2023, then plummeted by 35.26% to $219.4 million in 2024, then fell by 29.11% to $155.5 million in 2025.
  • Its Current Assets was $155.5 million in Q3 2025, compared to $192.5 million in Q2 2025 and $217.3 million in Q1 2025.